Diabetic Peripheral Neuropathy Market is segmented By Treatment (Pain Management Drugs, Gene Therapies), By Disease (Type 2 Diabetic Peripheral Neuropathy, Type 1 Diabetic Peripheral Neuropathy), By Therapy (Antidepressants, Anticonvulsants), By Patient Population (Adult Patients, Geriatric Patients), By Geography (North America, Latin America, Asia Pacific, Europe, Middle East, and Africa). The report offers the value (in USD billion) for the above-mentioned segments.
Market Size in USD
CAGR9.7%
Study Period | 2024 - 2031 |
Base Year of Estimation | 2023 |
CAGR | 9.7% |
Market Concentration | High |
Major Players | Helixmith, Aptinyx, WinSanTor, Inc., Regenacy Pharmaceuticals, Grünenthal GmbH |
The diabetic peripheral neuropathy market is estimated to be valued at USD 4.64 Bn in 2024 and is expected to reach USD 8.89 Bn by 2031, growing at a compound annual growth rate (CAGR) of 9.7% from 2024 to 2031. The market is primarily driven by the rising global prevalence of diabetes and growing geriatric population worldwide who are at a higher risk of developing diabetic peripheral neuropathy (DPN).